Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
New Advances and Challenges in Radiation Oncology for Gynaecological Malignancies
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Advances and Challenges in Radiation Oncology for Gynaecological Malignancies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 2104

Special Issue Editors

Dr. Amelia Barcellini

E-Mail Website
Guest Editor
1. Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, 27100 Pavia, Italy
2. Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy
Interests: carbon ion radiotherapy; proton beam radiotherapy; gynaecologycal oncology; rare tumor; radiobiology
Dr. Noriyuki Okonogi

E-Mail Website
Guest Editor
QST Hospital, National Institutes for Quantum Science and Technology, Chiba 263-0024, Japan
Interests: carbon ion radiotherapy; brachytherapy; gynaecologycal oncology; rare tumor; radiobiology

Special Issue Information

Dear Colleagues,

Radiation therapy plays a crucial role in the treatment of gynaecological tumors. The main indications for radiotherapy in this group of cancers are found in the cervix, endometrium, vagina, and vulva; however, in recent years radiotherapy has been proven to be an appealing alternative for oligometastatic ovarian cancers, especially in cases of chemorefractory disease or intolerance to systemic agents. Research on radiation oncology for gynaecological tumors is currently aimed at achieving the rapid evolution of and changes in radiobiology, technology, and planning systems. On the one hand, biology is being evaluated as a method for selecting patients for treatments; on the other hand, fractionation schedules and their combinations of new drugs are objects of study in several working groups.

This Special Issue wants to focus on basic science in addition to translational and clinical research on the application of new radiation techniques in order to have a more complete comprehension of the response and toxicity after radiation therapy in gynecological malignancies. Topics of interest could include, but are not limited to, particle radiotherapy, brachytherapy, stereotactic radiotherapy, BNCT, the application of radiotherapy on rare gynecological tumors, 2D–3D and animal radiobiological models, radiosensitizers and radioprotectors, combination treatments, immune radiobiology, and the tumor microenvironment. We also welcome manuscripts related to the clinical impact of radiation therapy on gynecological tumors and the impact of new advances in decreasing/preventing toxicities (i.e., planning systems, radiobiological models, image-guided techniques, and omics, but also new approaches such as pre- and post-rehabilitation techniques).

Since IJMS is a journal of molecular science, thus pure clinical studies will not suitable for our journal. But clinical or pure model submissions with biomolecular experiments are welcomed. 

Dr. Amelia Barcellini
Dr. Noriyuki Okonogi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynaecological tumors
  • rare gynaecological tumors
  • pre-clinical models
  • animal models
  • radiobiology
  • radiation oncology
  • particle beam radiotherapy
  • brachytherapy
  • toxicity
  • omics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1861 KiB  
Article
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
by Noriyuki Okonogi, Kazutoshi Murata, Shigeru Yamada, Yuji Habu, Makoto Hori, Tomoya Kurokawa, Yosuke Inaba, Tadami Fujiwara, Yasuhisa Fujii, Michiko Hanawa, Yohei Kawasaki, Yoko Hattori, Kazuko Suzuki, Kyoko Tsuyuki, Masaru Wakatsuki, Masashi Koto, Sumitaka Hasegawa, Hitoshi Ishikawa, Hideki Hanaoka, Makio Shozu, Hiroshi Tsuji and Hirokazu Usuiadd Show full author list remove Hide full author list
Int. J. Mol. Sci. 2023, 24(13), 10565; https://doi.org/10.3390/ijms241310565 - 23 Jun 2023
Cited by 4 | Viewed by 1825
Abstract
We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with [...] Read more.
We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with newly diagnosed histologically proven locally advanced cervical cancer were enrolled. All patients received 74.4 Gy of CIRT in 20 fractions and concurrent weekly cisplatin (chemo-CIRT) at a dose of 40 mg/m2. Durvalumab was administered (1500 mg/body) at weeks two and six. The primary endpoint was the incidence of adverse events (AEs) and serious AEs (SAEs), including dose-limiting toxicity (DLT). All three enrolled patients completed the treatment without interruption. One patient developed hypothyroidism after treatment and was determined to be an SAE. No other SAEs were observed. The patient recovered after levothyroxine sodium hydrate treatment. None of the AEs, including hypothyroidism, were associated with DLT in the present study. All three patients achieved complete responses within the CIRT region concerning treatment efficacy. This phase 1b trial demonstrates the safety of combining chemo-CIRT and durvalumab for locally advanced cervical cancer in the early phase. Further research is required as only three patients were included in this study. Full article
(This article belongs to the Special Issue New Advances and Challenges in Radiation Oncology for Gynaecological Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop